Ticker Details
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.
IPO Date:	September 7, 2005
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$6.47B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.50 | 2.21%
Avg Daily Range (30 D):	$4.28 | 1.56%
Avg Daily Range (90 D):	$4.37 | 1.89%

Institutional Daily Volume
Avg Daily Volume:	.26M
Avg Daily Volume (30 D):	.3M
Avg Daily Volume (90 D):	.21M

Trade Size
Avg Trade Size (Sh.):	88
Avg Trade Size (Sh.) (30 D):	37
Avg Trade Size (Sh.) (90 D):	33

Institutional Trades
Total Institutional Trades:	5,746
Avg Institutional Trade:	$3.33M
Avg Institutional Trade (30 D):	$9.71M
Avg Institutional Trade (90 D):	$7.94M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.49M
Avg Closing Trade (30 D):	$16.55M
Avg Closing Trade (90 D):	$9.56M
Avg Closing Volume:	30.08K

News

Jul 6, 2026 @ 11:35 AM CRISPR Therapeutics vs. Viking Therapeutics: Which... Source: Erin Kennedy

Jun 12, 2026 @ 8:05 PM XOMA Royalty Corporation Declares Quarterly Prefer... Source: Globe Newswire

Jun 10, 2026 @ 11:00 AM Ligand Announces 2026 Investor Day in New York Cit... Source: Na

Jun 7, 2026 @ 12:28 PM A Ligand Pharmaceuticals (LGND) Insider Sold 5,000... Source: Cory Renauer

May 4, 2026 @ 5:25 PM Villere St Denis Liquidates $18 Million Euronet Wo... Source: Eric Trie

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$7.9	$-.67	$2.33
Diluted EPS	$7.43	$-.67	$2.18
Revenue	$274.48M	$51.72M	$59.67M
Gross Profit
Net Income / Loss	$153.56M	$-13.35M	$44.78M
Operating Income / Loss	$94.59M	$17.37M	$13.84M
Cost of Revenue
Net Cash Flow	$67.03M	$-59.83M	$35.55M
PE Ratio

Splits
Nov 19, 2010	1:6